Arvinas (NASDAQ:ARVN) Shares Down 5.1% - Time to Sell?

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report)'s stock price dropped 5.1% during trading on Friday . The company traded as low as $8.51 and last traded at $8.54. Approximately 439,205 shares changed hands during mid-day trading, a decline of 53% from the average daily volume of 925,893 shares. The stock had previously closed at $9.00.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Morgan Stanley lowered their price target on Arvinas from $48.00 to $12.00 and set an "equal weight" rating on the stock in a report on Thursday, March 13th. Citigroup reduced their price objective on Arvinas from $28.00 to $19.00 and set a "neutral" rating for the company in a research report on Friday, March 7th. Oppenheimer cut Arvinas from an "outperform" rating to a "market perform" rating in a research report on Tuesday, March 11th. Stifel Nicolaus reduced their price target on shares of Arvinas from $63.00 to $51.00 and set a "buy" rating for the company in a research report on Wednesday, February 12th. Finally, BTIG Research started coverage on shares of Arvinas in a research note on Tuesday, December 10th. They issued a "buy" rating and a $69.00 price objective on the stock. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Arvinas has a consensus rating of "Moderate Buy" and a consensus target price of $37.47.

Arvinas Trading Down 5.6 %

The company has a market cap of $559.12 million, a PE ratio of -2.94 and a beta of 1.95. The business's 50 day moving average is $15.87 and its two-hundred day moving average is $21.00.

Remove Ads

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the business earned ($2.53) EPS. As a group, equities research analysts predict that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Noah Berkowitz sold 8,658 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the transaction, the insider now owns 110,023 shares of the company's stock, valued at approximately $945,097.57. The trade was a 7.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John G. Houston sold 31,338 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the transaction, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock worth $769,402 in the last three months. 5.23% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arvinas

A number of hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in Arvinas in the 4th quarter worth approximately $28,000. KBC Group NV grew its holdings in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after purchasing an additional 1,255 shares in the last quarter. Quantbot Technologies LP increased its position in Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after purchasing an additional 2,601 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Arvinas during the fourth quarter valued at $171,000. Finally, Tema Etfs LLC bought a new position in Arvinas during the fourth quarter valued at $227,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.